Ovarian cancer is generally detected in late stages and is difficult to cure as it spreads to whole body. In most of the cases, it starts in the fallopian tubes and spreads to ovaries and then whole body. There are 3 different types of cells of the fallopian tube and ovaries which can turn into 3 different tumors with cancerous and low malignant potential nature. Prevalence of ovarian cancer is more in the women of older ages and ranks 8th most commonly occurring cancer in women.
High prevalence of ovarian cancer in North America and Asia Pacific is the major factor driving the global ovarian cancer market. Rising awareness regarding ovarian cancer due to surge in the fatality rates across the globe and ongoing research and development in the ovarian cancer diagnostics are some of the other factors supporting the market growth.
However, Lack in the proper diagnostics of ovarian cancer and scarcity of the skilled professional in the diagnostics field are some of the factors which are anticipated to hamper the market growth. Apart from this, high cost of the treatment and poor healthcare infrastructure and services in the developing regions including Latin America and Africa are expected to restrain the market growth further.
The global ovarian cancer market is segmented into type, treatment, end user, and region.
Based on type, the global ovarian cancer market is segmented into epithelial tumors, germ cell tumors, and stromal tumors. Among type, germ cell tumors segment is expected to experience steady growth.
Based on treatment, the market is segregated into diagnosis, therapeutic treatment, and surgery. Diagnosis is further sub-segmented into computed tomography (CT) scans, Ultrasound, Barium enema x-ray, Magnetic resonance imaging (MRI) scans, Chest x-ray, Positron emission tomography (PET) scan, and other diagnostic tests. Therapeutic treatment is further divided into chemotherapy, radiation therapy, targeted therapy, hormone therapy, and other therapeutic treatments.
On the basis of end user, the market is segmented into hospitals, diagnostic centers, drug stores, online pharmacies, and other end users. Amongst end user, diagnostic centers and drug stores are expected to mark significant growth owing to the leaning trend towards advanced diagnostics and ease of online shopping.
In terms of region, the global ovarian cancer market is segmented into North America, Europe, Asia Pacific, Latin America and the Middle East & Africa (LAMEA).
Got questions about your regional growth of
ovarian cancer market?
Just drop us a line or call on +1 646 480 7505
North America is expected to dominate the ovarian cancer market owing to the high prevalence of ovarian cancer and availability of advanced healthcare facilities & diagnostic centers in the region. Moreover, huge geriatric population pool is the other factor which is expected to escalate the market growth in the region.
Europe is forecasted to experience steady growth owing to the presence of major pharmaceutical and biotechnology companies in the region. Additionally, favorable government policies and availability of advanced diagnostic centers in the region are other factors expected to positively influence the ovarian cancer market growth.
Asia Pacific is expected to experience fastest growth with highest CAGR among regions. Swift growth of ovarian cancer market in Asia Pacific is attributed to the higher prevalence of ovarian cancer in some parts of Asia Pacific. Along with this, huge geriatric population pool is supporting the market growth. According to the National Institute of Cancer Prevention and Research, ovarian cancer is the 3rd leading type of cancer among women in India with incidence rate ranging between 5.4 and 8.0 per 100,000 women.
Some of the major players in the market are Bristol Myers Squibb Company, AstraZeneca, Genentech Inc., Eli Lilly and Company, Novogen, Inc., F. Hoffman-La Roche Ltd., GlaxoSmithKline plc, Boehringer Ingelheim GmbH, Janssen Pharmaceuticals, Inc., Tesaro, Aetera Zenteris Inc., and Clovis Oncology.
Some of the other players with products in the late pipeline stage are Pfizer, AbbVie, ImmunoGen, Johnson & Johnson, Boehringer Ingelheim, and Oasmia Pharmaceuticals.
By End User